Clinical Development & Study Design Service

Protheragen provides a Specialized Clinical Development and study design framework specifically engineered to accelerate the delivery of transformative anti-obesity therapies to the global market. As metabolic disorders reach pandemic proportions, the demand for sophisticated, multi-mechanism weight management solutions, including GLP-1/GIP agonists and novel thermogenic agents, has never been higher. Our service integrates deep physiological expertise with advanced regulatory strategy to ensure that every study protocol is mathematically robust and clinically meaningful. We bridge the gap between early-stage molecular discovery and large-scale outcomes trials by focusing on high-quality endpoints, patient retention strategies, and rigorous safety monitoring.

Breaking Through Obesity Treatment: An Accelerator from Innovative Discovery to Market Access

Protheragen provides an end-to-end service portfolio tailored to the unique physiological and regulatory demands of anti-obesity drug development. Our offerings span the Entire Clinical Lifecycle, ensuring scientific integrity from initial human exposure to post-market surveillance.

• Early Phase and Exploratory Development

We design and execute phase I first-in-human (FIH) studies with a specific focus on metabolic safety and tolerability. This includes specialized single ascending dose (SAD) and multiple ascending dose (MAD) designs that incorporate early pharmacodynamic markers to evaluate metabolic rate changes and hormonal responses.

• Pivotal Phase II and III Programs

Our team manages large-scale phase II dose-ranging trials and phase III pivotal studies required for global registration. We provide expert guidance on weight loss maintenance phases and the complex statistical handling of titration schedules, ensuring that efficacy data is robust enough to support competitive market labels.

• Specialized Metabolic Investigations

We offer dedicated protocols for bioequivalence (BE) studies and drug-drug interaction (DDI) assessments, which are critical for obesity patients often on concomitant medications for hypertension or dyslipidemia. Our services also include long-term cardiovascular outcome trials (CVOT) to satisfy rigorous safety mandates.

• Body Composition and Endpoint Optimization

Beyond simple weight metrics, we provide standardized imaging services including DXA and 3D optical surface imaging. These services allow for the precise quantification of fat mass reduction versus lean muscle preservation, providing a deeper clinical narrative of the drug's therapeutic value.

• Pediatric and Niche Population Studies

We extend our clinical expertise to pediatric obesity research and studies involving patients with secondary metabolic complications. This includes specialized recruitment and ethical monitoring frameworks designed for younger populations and those with high-risk comorbidities.

• Digital and Device Integration

For sponsors developing digital therapeutics or weight management devices, we offer integrated study designs that combine clinical rigor with user engagement analytics, ensuring that behavioral interventions are validated alongside pharmacological or mechanical components.

To Establish a Roadmap for Your Clinical Quality, Contact Protheragen Today.

Workflow

The clinical development process is a highly structured, five-stage operational journey, meticulously engineered to maximize trial efficiency while systematically neutralizing potential regulatory friction. By aligning each phase with international compliance milestones, we ensure that the transition from strategic design to final reporting is both seamless and audit-ready, allowing sponsors to move through the development pipeline with enhanced predictability and scientific rigor.

• Clinical Target Product Profile (TPP) Alignment

We first define the TPP based on your candidate drug characteristics (e.g., long-acting GLP-1 agonists or oral small molecules). By benchmarking against current weight loss market leaders, we establish optimal efficacy thresholds, safety boundaries, and differentiated selling points, setting the strategic tone for the entire clinical development plan (CDP).

• Scientific Protocol Architecture & Endpoint Selection

A protocol architecture is developed by our metabolic expert team. Beyond basic percentage weight change, we integrate key metrics through a hierarchical endpoint strategy, including body composition optimization (DXA assessment), metabolic flexibility (fasting glucose/insulin sensitivity), and condition-specific endpoints for comorbidities, ensuring scientific depth in the data.

• Advanced Statistical Modeling & Simulation

Complex statistical simulations optimize trial sample size. We perform predictive modeling for the weight-loss trial-specific dropout rate during dose-escalation periods, designing missing data handling strategies (e.g., multiple imputation methods). This ensures robust statistical power that meets regulatory standards even during extended follow-up periods of 52-72 weeks.

• Global Regulatory De-Risking & Synchronization

We proactively align with the latest FDA, EMA, and NMPA guidelines during the design phase (e.g., long-term cardiovascular safety requirements for anti-obesity drugs). Our protocols incorporate upfront regulatory risk assessments, simulating regulatory review logic to identify and rectify compliance gaps that could cause delays, ensuring global audit resilience.

• Patient-Centric Experience & Adherence Design

We humanize trial workflows by modeling the psychological and physiological characteristics of long-term obesity treatment. This includes optimizing titration schedules to maximize gastrointestinal tolerance and designing participant engagement and education programs. By reducing participation barriers at the design stage, we effectively lower clinical dropout rates and enhance data collection integrity.

Applications

• Next-Generation Pharmacological Modalities

Our study design services are applicable across a wide spectrum of therapeutic modalities. This includes small molecule weight loss drugs, injectable biologics (such as GLP-1 and GIP receptor agonists), and novel nutritional interventions that target metabolic pathways at the molecular level.

• Integrated Metabolic and Surgical Therapies

We apply our expertise to metabolic surgery support therapies and the evaluation of medical devices designed for obesity management. Our protocols are designed to measure the synergistic effects of combined pharmacological and physical interventions on long-term weight maintenance.

• Chronic Comorbidity Management

Our application scope extends to related comorbid conditions where weight management is a primary clinical goal. This includes type 2 diabetes (T2D), non-alcoholic steatohepatitis (NASH/MASH), and polycystic ovary syndrome (PCOS), ensuring a holistic approach to metabolic health.

Advantages

Contact Us to Explore our Full Suite of Clinical Support Services.

Customer Review

Frequently Asked Questions

1. Can you assist with the selection of primary endpoints for metabolic studies?

   Yes, our medical team specializes in identifying and validating endpoints that satisfy both rigorous regulatory requirements and the evidentiary needs of commercial payers. This involves a strategic balance between traditional metrics, such as the percentage change in total body weight from baseline, and advanced metabolic indicators like improvements in insulin sensitivity (HOMA-IR), lipid profiles, and liver fat content, providing a multi-dimensional view of therapeutic efficacy.

2. What regulatory agencies are you familiar with?

   Protheragen has extensive experience collaborating with major global authorities, including the FDA, EMA, NMPA, and PMDA. We understand the nuanced differences in guidance between these regions, from differing requirements for cardiovascular safety assessments to regional preferences for comparator arms. Our global regulatory intelligence ensures your study is designed to meet harmonized standards, facilitating a smoother multi-regional submission process.

3. How can I get started with a consultation?

   Getting started is a straightforward process; you can reach out via our secure inquiry portal to schedule an initial confidential discussion with our metabolic strategy team. During this consultation, we will review your current pipeline objectives, identify potential regulatory or operational risks, and outline a tailored roadmap for your clinical program, providing the strategic clarity needed to move your therapy forward.

Protheragen is dedicated to being the strategic heartbeat of your clinical development program. Our deep-rooted expertise in metabolic science ensures that your anti-obesity therapy is given the best possible chance for regulatory approval and market success. We invite you to collaborate with us to build a healthier future. Welcome to contact us for more information and to discuss your project.